MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Free Cash flow
-$3,140K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Change in fair value of financia...
    • Loss on debt extinguishment
    • Borrowings under short-term debt...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Trade accounts receivable
    • Inventories
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-11,036
-5,465
2,788
-1,569
Gain on change in accounting estimates on contingent royalty liability
-
-
0
1,933
Loss on debt extinguishment
-2,192
-
-
-
Change in fair value of financial instruments
-5,745
-162
131
-1,845
Inventory write-down for excess & obsolescence
118
192
834
0
Loss on contingent liability
61
58
29
0
Stock-based compensation
0
15
42
23
Depreciation
4
4
5
4
Amortization of intangible asset
14
75
89
80
Noncash interest expense
626
614
606
595
Noncash right-of-use asset amortization
32
32
13
34
Net loss on disposal or impairment of property and equipment
-
-
0
0
Gain on accounts payable and accrued expenses settlements
-
-
18
11
Trade accounts receivable
1,937
-11,920
8,045
-499
Inventories
265
761
-25
-222
Prepaid and other assets
-83
130
144
-423
Accounts payable
29
-1,605
1,547
-656
Accrued expenses and other liabilities
600
-1,636
3,452
502
Accrued compensation
682
-1,092
-1,022
360
Contingent liabilities
-56
-50
-24
-50
Operating lease liabilities
-32
-32
-15
-32
Net restricted cash and cash equivalents used in operating activities
-3,140
2,301
31
336
Payments related to asset acquisition
-
-
-
0
Payments related to intangible asset acquisition
-
-
57
-
Purchases of property and equipment
0
2
3
0
Net restricted cash and cash equivalents used in investing activities
0
-2
-3
0
Proceeds from issuance of aditxt notes related party
-
-
0
0
Borrowings under short-term debt and notes carried at fair value
1,068
-
0
0
Payments under short-term debt and notes carried at fair value
22
498
278
244
Cash paid for financing costs
-
-
12
-
Net restricted cash and cash equivalents provided by financing activities
1,046
-498
-290
-244
Net change in restricted cash and cash equivalents
-2,094
1,801
-262
92
Restricted cash and cash equivalents, beginning of period
2,379
578
840
741
Restricted cash and cash equivalents, end of period
285
2,379
578
840
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Borrowings undershort-term debt and notes ...$1,068K (178.85%↑ Y/Y)Net restricted cashand cash...$1,046K (-56.87%↓ Y/Y)Canceled cashflow$22K Net change inrestricted cash and cash...-$2,094K (-30014.29%↓ Y/Y)Canceled cashflow$1,046K Change in fair value offinancial instruments-$5,745K (-523.99%↓ Y/Y)Loss on debtextinguishment-$2,192K Accrued compensation$682K (378.37%↑ Y/Y)Noncash interestexpense$626K (-46.27%↓ Y/Y)Accrued expenses andother liabilities$600K (16.73%↑ Y/Y)Inventory write-down forexcess & obsolescence$118K (-33.71%↓ Y/Y)Prepaid and other assets-$83K (-7.79%↓ Y/Y)Loss on contingentliability$61K (144.00%↑ Y/Y)Noncash right-of-useasset amortization$32K (-47.54%↓ Y/Y)Accounts payable$29K (104.09%↑ Y/Y)Amortization of intangibleasset$14K (-95.76%↓ Y/Y)Depreciation$4K (-60.00%↓ Y/Y)Payments undershort-term debt and notes ...$22K (-94.26%↓ Y/Y)Net restricted cashand cash...-$3,140K (-33.11%↓ Y/Y)Canceled cashflow$10,186K Net loss-$11,036K (-1232.85%↓ Y/Y)Trade accountsreceivable$1,937K (139.55%↑ Y/Y)Inventories$265K (-47.73%↓ Y/Y)Contingent liabilities-$56K (86.82%↑ Y/Y)Operating leaseliabilities-$32K (48.39%↑ Y/Y)

Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences, Inc. (EVFM)